Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
POTS-associated Conditions and Management Strategies
Author(s): Alexis Cutchins , Svetlana Blitshteyn , Rebecca Steinberg Added: 2 years ago
Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder that presents with positional tachycardia, amongst many other symptoms. Evidence for treatment options remains limited, and there are a multitude of associated conditions with overlapping symptoms which can make the diagnosis and management of POTS a difficult experience for providers and patients alike.This broadcast… View more

Electrophysiology & Arrhythmia

COVID-19
ESC 25: EMORI-HCM: Electromagnetically Optimised Right Ventricular Pacing for oHCM
Author(s): Ahran D Arnold Added: 8 months ago
ESC Congress 2025 - EMORI-HCM finds that right ventricular pacing (iRVP) improves symptoms in obstructive hypertrophic cardiomyopathy (oHCM) patients.Dr Ahran Arnold (Imperial College London, UK) discusses findings from the EMORI-HCM study, exploring electro-mechanically optimised right ventricular pacing as a novel therapeutic approach for patients with oHCM.This interventional trial examined… View more

Intervention

Electrophysiology & Arrhythmia
Navigating Mitral and Tricuspid Valve Disease: Diagnosis, Quality of Life, and Patient-Centered Care
Author(s): Suzanne Arnold , Colin Barker, Start date: Aug 07, 2025
Mitral and tricuspid regurgitation remain under-recognised and undertreated despite their significant impact on symptoms, quality of life, and outcomes. In this expert-led webinar, Suzanne V. Arnold, MD (Saint Luke’s Health System, Kansas City, US) offers practical guidance on recognising heart valve disease early, navigating referral pathways, and integrating patient-centred data into everyday… View more

Intervention
ACC 26: RECOVER-Autonomic - Ivabradine for Post-COVID POTS
Author(s): Pam Taub Added: 1 month ago
American College of Cardiology Congress 2026 – Dr Pam Taub (University of California San Diego, La Jolla, US) joins us to discuss results from the RECOVER-Autonomic platform trial (NCT06305806; Kanecia Obie Zimmerman), evaluating the impact of ivabradine on orthostatic intolerance, quality of life, and heart rate in post-COVID POTS.This randomised, placebo-controlled appendix trial enrolled 181… View more

Prevention & Chronic Conditions

COVID-19
NY Valves 25: TRISCEND II Substudy
Author(s): Added: 10 months ago
New York Valves 25 - A substudy of TRISCEND II investigating the effect of transcatheter tricuspid valve replacement (TTVR) on preference-weighted health status showed significant benefits in patients who received TTVR.We are joined by Dr Suzanne Arnold (Saint Luke's Mid America Heart Institute, US) to discuss the findings from a substudy of the TRISCEND II trial, which aimed to create an… View more

Intervention
Myxoma Found Incidentally Causing Severe Functional Mitral Stenosis
Author(s): Moaaz Amir , Rawan Amir , Farnoosh Rahimi Added: 7 months ago

Imaging & Diagnostics
AHA 24: The ENDEAVOR Trial
Author(s): Added: 1 year ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the… View more

Heart Failure
ACC 26: ORBITA-CTO - PCI vs Placebo in Stable Angina
Author(s): Sarosh Khan , John Davies Added: 1 month ago
American College of Cardiology Congress 2026 - Dr Sarosh Khan and Dr John Davies (Essex Cardiothoracic Centre, Basildon, UK) join us to discuss results from the ORBITA-CTO trial (NCT05142215; Mid and South Essex NHS Foundation Trust), a randomised, placebo-controlled study evaluating CTO PCI versus placebo for the relief of stable angina.This double-blind, randomised, placebo-controlled pilot… View more

Intervention

Prevention & Chronic Conditions
AHA 25: MAPLE-HCM Responder Analysis
Author(s): Andrew Wang Added: 6 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive… View more

Heart Failure
Dr Mauro Lencioni
Job title: Consultant Cardiologist & Electrophysiologist
Mauro Lencioni is a cardiologist at the Queen Elizabeth Hospital, Birmingham. His interests are the treatment of cardiac arrhythmias and the effects of arrhythmia symptoms on quality of life. View more